COSCIENS Biopharma shifts focus to natural-based products after its Phase 3 DETECT trial for macimorelin in Childhood Growth Hormone Deficiency (CGHD) failed.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.